Therapy’s Shadow: A Short History of the Study of Resistance to Cancer Chemotherapy by Peter Keating et al.
REVIEW ARTICLE
published: 07 May 2013
doi: 10.3389/fphar.2013.00058
Therapy’s shadow: a short history of the study of resistance
to cancer chemotherapy
Peter Keating1*, Alberto Cambrosio2, Nicole C. Nelson2, Andrei Mogoutov 3 and Jean-Philippe Cointet 3,4,5
1 Department of History, Université du Québec à Montréal, Montreal, QC, Canada
2 Department of Social Studies of Medicine, McGill University, Montreal, QC, Canada
3 IFRIS (Institut Francilien Recherche Innovation Société), Université Paris-Est, Marne-la-Vallée, France
4 INRA-SenS (Sciences en Société), Université Paris-Est, Marne-la-Vallée, France
5 Institut des Systèmes Complexes – Paris lˆle-de-France, Paris, France
Edited by:
Gerald Batist, McGill University,
Canada
Reviewed by:
Todd Skaar, Indiana University Medical
Center, USA
Marc Poirot, Institut National de la
Santé et de la Recherche Médicale,
France
*Correspondence:
Peter Keating, Department of History,
Université du Québec à Montréal,
1255 St-Denis, Montreal, QC H2X3R7,
Canada.
e-mail: keating.peter@uqam.ca
This article traces the history of research on resistance to drug therapy in oncology using
scientometric techniques and qualitative analysis. Using co-citation analysis, we generate
maps to visualize subdomains in resistance research in two time periods, 1975–1990 and
1995–2010. These maps reveal two historical trends in resistance research: first, a shift in
focus from generic mechanisms of resistance to chemotherapy to a focus on resistance to
targeted therapies and molecular mechanisms of oncogenesis; and second, a movement
away from an almost exclusive reliance on animal and cell models and toward the gener-
ation of knowledge about resistance through clinical trial work. A close reading of highly
cited articles within each subdomain cluster reveals specific points of transition from one
regime to the other, in particular the failure of several promising theories of resistance to
be translated into clinical insights and the emergence of interest in resistance to a new
generation of targeted agents such as imatinib and trastuzumab. We argue that the study
of resistance in the oncology field has thus become more integrated with research into
cancer therapy – rather than constituting it as a separate domain of study, as it has done in
the past, contemporary research treats resistance as the flip side to treatment, as therapy’s
shadow.
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INTRODUCTION
Resistance to chemotherapy and other oncology drugs has long
been a topic of interest to both researchers and clinicians, but
how has research in this field changed over time, particularly with
the introduction of targeted therapies for many common types of
cancer? We argue that the study of resistance to cancer chemother-
apy has undergone several major transformations over the last
15 years, both at the scientific and the organizational level. On
the scientific side, the research field has seen a shift from generic
mechanisms of resistance to chemotherapy to specific molecu-
lar mechanisms of cancer progression, corresponding with the
advent of targeted cancer therapies. The discovery of oncogenes
and oncogenic pathways has directed cancer therapeutics away
from cell-kill to pathway disruption, and toward the creation of
new drugs, mainly small molecules and antibodies. These new, tar-
geted drugs do as much to unveil the biological processes of cancer
initiation and progression as they do to shut them down.
Second, experimental work on resistance has moved from an
almost exclusive focus on pre-clinical systems to clinical experi-
mental studies. New forms of clinical research – biomarker trials,
neo-adjuvant studies, and so on – have reoriented the experimen-
tal basis of resistance studies from animal models and cell lines to
a mix of animal models, materials derived from human patients,
and clinical studies. Rather than merely establishing drug effi-
cacy, many clinical trials now function like a clinical experimental
system, where the study of clinical efficacy is accompanied by a
series of biological questions that treat resistance more as an inte-
gral component of therapy – therapy’s shadow, so to speak – and
less as simply the failure of therapy.
MAPPING THE FIELD
To analyze the development of the resistance field over time, we
combined a qualitative review of the literature with a scientomet-
ric technique known as co-citation analysis (Small, 1973; Garfield
et al., 1978; Vargas-Quesada and de Moya-Anegón, 2007). What is
co-citation analysis and what are the advantages of this technique
over simpler indicators, such as a list of most-cited articles? In
contrast to bibliometric productivity measures (number of arti-
cles, number of citations given to articles, articles published in high
impact-factor journals, etc.), co-citation mapping techniques use
sophisticated information visualization tools that make complex
relations and configurations visible without reducing them to a
few, often crude statistical indicators. A list of articles is just that:
a list of articles; co-citations networks provide not only insights
about which articles researchers consider major contributions to
the development of their domain, but they also enable us to visu-
alize clusters of related references as the constitutive subdomains
of a given research area at a given point in time.
Co-citation networks are one of two possible visualization tech-
niques that can be used to map different aspects of a given field’s
structure, development, and dynamics, the other, more easy-to-
grasp, being inter-citation networks. Inter-citation is simply the
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association established when an article A (the citing reference)
cites an article B (the cited reference). Co-citation is a subtler
notion: two references A and B are co-cited if they frequently
appear together in the reference list of other articles. Co-citation
networks then display the most-cited references as nodes, with
co-citation links connecting frequently co-cited references. The
assumption is that cited references, because of their co-citation
patterns, will be gathered together naturally into highly cohesive
subgroups that provide a cognitive map of core contributions to
a field, as they display the internal substructures and constitu-
tive subdomains within that field. Inter-citation maps, in contrast,
provide a more comprehensive view of a domain by showing the
relations between a large number of references, even those that do
not qualify as major contributions. Thus, inter-citation empha-
sizes the organizational components of a domain and co-citation
its cognitive dynamics. In other words, whereas inter-citations cap-
ture the circulation of ideas throughout a given domain without
hierarchical orderings, co-citations display the epistemic founda-
tions of a given field at a particular point in time. An additional
twist in the co-citation approach is to add a temporal axis to the
resulting maps, in order to investigate the contribution of both
older and more recent articles to the formation of a given domain.
Rather than showing the actual historical development of a field,
temporal co-citation maps reveal judgments about the relevant
history of a field as perceived at a given moment by the authors of
the articles used as source data.
Having opted, for the aforementioned reasons, to analyze the
study of resistance using co-citations maps, we searched Medline
for articles corresponding to the MeSH keyword (Drug Resistance,
Neoplasms) introduced in 1995, and to the MeSH keywords (Drug
Resistance AND Neoplasms) for the pre-1995 period. Resort to
the MeSH ontology allowed us to capture not only articles that use
the term “drug resistance” in their titles and abstract, but also, for
instance, those that specifically focus on a drug while not explicitly
mentioning that term. Since our goal was to analyze the trans-
formation of the field, we selected articles corresponding to two
different periods, the years 1976–1990 and 1995–2010, retrieving a
set of 4,229 articles for the former and 18,822 articles for the latter.
We positioned these two periods at the opposite ends of the time
spectrum to better capture differences between early and recent
research on resistance. The exact timespan of the two periods is
somewhat arbitrary, as we could have chosen slightly shorter or
longer periods, but this is inconsequential as co-citation analysis
only retains the most-cited references and the most frequent co-
citation links: both are relatively stable over short time periods.
Finally, in order to test whether trends uncovered by the com-
parison of these two periods extended to the most recent years,
we created a third dataset covering the years 2010 to November
2012.
While the MeSH keywords available in Medline allow for
a very specific search strategy, a co-citation analysis requires
lists of cited articles as provided by bibliometric databases such
as Thomson Reuters’ Web of Science (WoS). Using a recently
developed batch-matching technique to identify WoS references
corresponding to Medline datasets (Leydesdorff and Opthof,
2013), we retrieved 16,162 matching references (86%) for the
1995–2010 period, and 3,145 matching references (74%) for
the 1976–1990 period. The missing references belonged to jour-
nals not included in the WoS: while the coverage of bio-
medical journals is less extensive in WoS than PubMed, WoS
included all most frequently cited journals. Finally, for the
third dataset covering the years 2010–November 2012 we found
6,162 Medline references and 5,484 WoS matching references
(89%).
We analyzed the three WoS datasets using the software plat-
form CorTexT (http://manager.cortext.net/), which comprises
algorithms designed to process bibliographic data and to per-
form several types of scientometric network analyses (Jones et al.,
2011; Cointet et al., 2012). In the present case, we selected a
distributional proximity measurement (Weeds and Weir, 2005)
to calculate co-citation links between the 200 most-cited refer-
ences. To display these links CorTexT applies a dynamic posi-
tioning algorithm that optimizes the location of all the nodes
by minimizing the overall strain in the network. CorTexT also
uses an automatic clustering algorithm to define (and color-
code) co-citation clusters, i.e., cohesive subsets of the network
that provide a high-level, fully bottom-up description of the
network. To facilitate interpretation, CorTexT adds color circles
around each cluster. Finally, we used CorTexT’s text-mining algo-
rithms, based on a Natural Language Processing (NLP) techniques
(Ananiadou and McNaught, 2006; Feldman and Sanger, 2007)
to extract multi-term concepts from the titles and abstracts of
the articles. Compared to the MeSH standardized keywords ret-
rospectively added to references by indexers, NLP-based terms
correspond to concepts actually used by the authors of arti-
cles. We were thus able to provide a preliminary, automatic
description of a cluster’s content by characterizing each clus-
ter with the concepts most specifically related to it. This was
followed by a more detailed, manual inspection of individual
references.
Figures 1 and 2 display the resulting maps for the 1976–
1990 and 1995–2010 periods. A comparison of the two maps
shows increased domain fragmentation. While each map dis-
plays distinct clusters, the map of the early period has a highly
interconnected central component and the more recent period
shows a number of specialized subdomains. Inspection of the
clusters reveals that while the 1976–1990 map contains a num-
ber of centrally positioned, interconnected clusters related to the
study of generic resistance mechanisms and multi-drug resis-
tance (MDR), the 1995–2010 period is characterized by separate
clusters that correspond to specific types of cancer and drugs
directed against pathways closely connected to those individ-
ual pathologies. For example, we can identify clusters devoted
to breast cancer, non-small cell lung cancer, prostate and ovar-
ian cancer, and chronic myelogenous leukemia. In the case of
chronic myelogenous leukemia, we have two distinct clusters
that appear to correspond to different stages of development:
first, to the initial exploration of the BCR-ABL translocation
and the development of imatinib, followed by a second set of
studies focusing on point mutations conferring resistance to
imatinib, and the development of drugs designed to overcome
this resistance. While MDR also appears as a cluster on the
1995–2010 map, the trend is clear: researchers’ attention has
shifted from MDR to targeted therapies and related molecular
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FIGURE 1 | Co-citation map of the 200 most-cited references in
articles published from 1976 to 1990 in the domain of
anti-neoplastic drug resistance.The 200 most-cited references are
represented by triangles whose size is proportional to the number of
citations. Two references are connected in the co-citation network if they
are frequently co-cited (i.e., jointly cited by other articles). Automatic
clustering techniques are used to rearrange co-cited references into
cohesive, color-coded sub-groups that provide a high-level description of
the different thematic domains characterizing the field development.
Natural-language processing algorithms are used to extract multi-term
concepts from the titles and abstracts of the citing references, and the
most specific multi-terms (as defined by a Chi-square measure) are used
to tag each cluster, thus providing information about the thematic
content of that cluster.
mechanisms, in particular signaling pathways. In spite of recent
calls to abandon histology (Bernards, 2012), this new perspec-
tive is still structured around the tissue of origin. The map
of the 2010–2012 period (Figure 3), shows this trend even
more clearly: in addition to a small MDR cluster (centered on
P-glycoprotein and ABC-transporter: see below), a cluster on
tumor stem cells and chemoresistance, and a cluster on platinum
resistance, we see two distinct breast cancer clusters (one on
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FIGURE 2 | Co Co-citation map of the 200 most-cited references in articles published from 1995 to 2010 in the domain of anti-neoplastic drug
resistance. See the legend of Figure 1 for explanations.
endocrine resistance, hormone receptors, and tamoxifen, the other
on HER2, trastzumab, and lapatinib), a colorectal cancer cluster
(KRAS and cetuximab), a non-small cell lung cancer-gefitinib clus-
ter, a melanoma cluster (BRAF and AKT), a chronic myelogenous
leukemia cluster (imatinib, nilotinib, dasatinib), and a mixed
prostate and pancreatic cancer cluster (sunitinib, angiogenesis, and
gemcitabine).
In what follows, we outline several historical strands of resis-
tance research in oncology and provide a more detailed, qualitative
examination of the transition from one period to the other, based
on the close reading of the key contributions displayed on the
corresponding maps.
EARLY SELECTION MODELS OF RESISTANCE AND THEIR
CLINICAL CORRELATES
The red cluster at the center of Figure 1 harbors the oldest ref-
erence of the map, namely the celebrated 1943 Genetics article
by Luria and Delbrück (1943) on bacterial chemotherapy, which
showed that it was not contact with antibiotics that produced
resistance: resistance preceded therapy. In the particular case of
bacterial resistance to viruses, resistant strains arose from muta-
tions independently of contact with the virus. Resistance, in other
words, was not an acquired immunity but the result of pre-existing
heterogeneity that arose spontaneously in cultures developed from
a single bacterium. The red cluster harbors another landmark
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FIGURE 3 | Co-citation map of the 200 most-cited references in articles published from 2010 to 2012 in the domain of anti-neoplastic drug resistance.
See the legend of Figure 1 for explanations.
paper, the 1964 article by Skipper et al. (1964) detailing the cell-
kill hypothesis, according to which a successful cancer treatment
entailed killing all cancer cells just as a successful antibiotic ther-
apy entailed the elimination of all the pathogenic bacteria. Cancer
chemotherapy in the 1960s was predicated on Skipper et al.’s
(1964) hypothesis (aligned with the Luria and Delbrück findings)
that unsuccessful therapy followed either the failure to eliminate
all the bacteria/neoplastic cells or the emergence of resistant bacte-
rial or cancerous clones. During this early period, mechanisms of
resistance to cancer chemotherapies were thus modeled on bacte-
rial chemotherapy and, in this regard, they were the mirror image
of the putative mechanisms for chemotherapy’s success. Figure 4
allows us to better visualize these historical contributions. Based
on the same dataset of Figure 1, using the same parameters and
showing the same clusters, Figure 4 adds a (logarithmic) timeline
thus ‘stretching’ each cluster to chronologically display its compo-
nents. While other early papers (e.g., Scatchard, Löwry, Kaplan)
correspond to methodological (statistical and biochemical) con-
tributions that tend to have long citation careers, both the Luria
and Delbrück, and the Skipper et al. (1964) paper refer to sub-
stantive, conceptual contributions that were clearly perceived as
forerunners for subsequent work.
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FIGURE 4 | Chronological co-citation map of the 200 most-cited references in articles published from 1976 to 1990 in the domain of anti-neoplastic
drug resistance. As compared to Figures 1–3, this Figure adds a logarithmic timeline and displays the components of each cluster chronologically.
Another relatively early key contribution from the red clus-
ter of Figure 1 that occupies a forerunner position in Figure 4
is Nowell’s (1976) article on the clonal evolution of tumor cell
populations that is cited in recent work on tumor heterogeneity
(Greaves, 2010) as the foundation of our current understanding of
this phenomenon. Nowell’s contribution followed from a number
of previous publications. They included Lloyd Law’s 1950s studies
of the action of folic acid analogs in mouse leukemic cells. Law,
in line with Luria and Delbrück hypothesis, found that “muta-
tion and selection constitute the mechanism by which resistant
leukemic cells develop” (Law, 1952). Parallel work by Makino
(1956) in Japan transferred the bacterial growth hypothesis from
the level of cells to the level of chromosomes, by developing an
experimental system that produced consistent and characteristic
chromosome patterns showing that the tumors developed from a
single “stem cell.” Hauschka (1961), from the Roswell Park Cancer
Institute, summarizing more than a decade’s work in this area in
a number of animal and tissue systems, concluded that the initial
cancer stem cell underwent a number of branching mutations in
the course of tumor development that included not only secondary
stem cell lines, but also chemotherapy and radiotherapy-resistant
clones. The limits of the analysis were, however, well known at
the time and, despite many advances, chromosome analysis and
the novel somatic cell hybridization techniques were still consid-
ered blunt instruments unable to detect changes at the level of
the gene. Hauschka’s complaint about his own techniques sum-
marized a general frustration: “This furtiveness of the genes,
coupled with the crudity of chromosomal hieroglyphs, irks the
quantitatively minded investigator who wants to attack neoplasia
in more articulate, molecular terms” (Hauschka, 1961). One of
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the reasons why these early publications, in contrast to Nowell’s
(1976) contribution, did not make it to the top-200 references
displayed on our maps, lies in the fact (mentioned by Nowell)
that the genomic instability and heterogeneous nature of neo-
plasia had not been at the center of these initial studies. Further
buttressed by immunological findings in the field of lymphopro-
liferative disorders, Nowell also drew a therapeutic implication for
his model, absent in previous work, that has decidedly modern
echoes. Given the heterogeneity of the clonal selection process,
he suggested that “each patient’s cancer may require individual
specific therapy and even this may be thwarted by emergence of
a genetically variant subline resistant to the treatment” (Nowell,
1976).
Also harbored within the central red cluster of Figure 1 are three
papers by Goldie et al. In the post-WWII period up to the end of
the 1970s, much of the inquiry into the mechanisms of therapeu-
tic resistance had been conducted outside of clinical research and,
with the exception of Nowell’s musings about the future of can-
cer treatment, few lessons had been drawn from such models for
therapy. The situation changed slightly, though not significantly, at
the end of the 1970s with the appearance of the Goldie–Coldman
hypothesis that proposed that tumor size could be related to the
possibility that at least one resistant phenotype would emerge in
the course of tumor development (Goldie and Coldman, 1979).
For instance, the larger the tumor, the greater the possibility that
it might harbor mutant clones. Drawing a direct line to therapy,
Goldie and Coldman proposed that debulking could thus be seen
as a means of reducing heterogeneity and thus the number of
resistance clones. Alternating chemotherapies could also be ratio-
nalized as a means of eliminating resistant phenotypes (Goldie
and Coldman, 1984). The somaticmutation theory, as they called it,
could also be used to justify shortening the time between surgery
and adjuvant therapy in order to decrease the possibility of the
emergence of mutant, resistant clones.
Although they drew clinical implications from a generic model
of resistance, in practice these propositions were justifications
of ongoing activities, and had already been rationalized under
the cell-kill hypothesis and its derivatives like the Norton–Simon
hypothesis (Norton and Simon, 1977). The somatic mutation the-
ory ultimately offered no specific guidelines for what to do in
clinical research. As Goldie himself admitted: “While the somatic
mutation theory provides predictions regarding broad strategic
principles, it makes no statement about specific drugs, combi-
nations, toxicity, etc. This sort of information will need to be
derived from clinical trials, appropriate experimental systems, and
the wisdom and experience of those who embark on these stud-
ies” (Goldie, 1983). In other words, while laboratory studies might
offer a reason for clinical studies, they offered little direction. This
would be a recurring theme in the field of studies of resistance for
many years to come.
MULTI-DRUG RESISTANCE
The 1980s saw the consolidation of work on MDR, identified in
shades of green and dark blue in the left and bottom of Figure 1.
First isolated as instances of cross-resistance in animal cell lines
selected for resistance to vinblastine and actinomycin D in the
late 1960s and early 1970s (Kessel et al., 1968; Biedler and Riehm,
1970), by the second half of the 1970s, MDR was correlated with
the expression of the P-glycoprotein (Juliano and Ling, 1976;
Riordan and Ling, 1979). The discoverers of P-glycoprotein, J. R.
Riordan’s group at the Hospital for Sick Children in Toronto, went
on to clone the gene for the protein, MDR-1 in 1985 (Riordan
et al., 1985), the same year that the term “ATP-binding cassette”
supergene family was defined (Gottesman et al., 2002).
At the NCI, the idea that MDR was the bottleneck in cancer
chemotherapy became known as the“the gospel of Bruce Chabner”
(the 1982–1995 Director of the NCI’s Division of Cancer Treat-
ment). As noted previously, Figure 2 also includes a component
devoted to MDR. As shown by the light green, dark blue, yellow,
and red clusters that run from top to bottom of Figure 2, signifi-
cant resources were directed to the study of MDR-1 throughout the
1980s (Endicott and Ling, 1989; Goldstein et al., 1989; Gottesman
and Pastan, 1993; Gottesman and Ling, 2006). Interest in MDR
mechanisms gained further interest with the discovery of the gene
for a second generic drug pump, MRP, in 1992 (Cole et al., 1992)
and the increasing entanglement of the biochemical mechanisms
in oncogene and anti-oncogene (tumor suppressor genes) activi-
ties (Borst et al., 2000). Indeed, the year MRP was discovered, the
promoter region of MDR-1 was found to be the target of RAS and
p53 protein products. Mutant p53 genes, in particular, were found
to activate rather than repress MDR-1 (Chin et al., 1992) There-
after, p53 was found to regulate apoptosis and was thus implicated
in a specific molecular pathway of resistance to anticancer agents
in general (Lowe et al., 1993; Doyle et al., 1998). More recently,
ABC drug transporters have crossed paths with models of cellu-
lar selection and the tumor stem cell theory (Dean et al., 2005).
While ABC-transporters are held to protect tumor stem cells from
chemotherapeutic agents thus creating resistant subpopulations
that have the capacity for long-term renewal, this insight has yet
to have a direct consequence for the clinic: “the stem-cell model
of drug resistance at present has little applicability” (Dean et al.,
2005).
Despite many successes in animals and cell culture that cor-
respond in Figure 1 to the central purple cluster of highly co-
cited articles that overlaps with the central red cluster (Tsuruo
et al., 1981), the first clinical trial showing success in the use of
a first-generation MDR inhibitor (cyclosporine) did not occur
until 2001 (List et al., 2001). By then, more than 15 companies
were pursuing research programs targeting novel, next-generation
MDR-1 and MRP inhibitors seeking monoclonal antibodies, anti-
sense oligonucleotides, and small molecules to block MDR activ-
ities (Persidis, 1999). The results have not been promising. As
Tamaki et al. concluded a decade later: “Three generations of
inhibitors later, we are still no closer to validating . . . the idea
that increased chemotherapy efficacy can be achieved by inhibi-
tion of transporter-mediated efflux” (Tamaki et al., 2011; see also
Robey et al., 2010; Falasca and Linton, 2012).
GENETIC MECHANISMS OF RESISTANCE
The 1980s also saw the emergence of the first genetic mecha-
nism for drug resistance: gene amplification of the dihydrofolate
reductase (DHFR) genes in methotrexate resistance (yellow, top-
right cluster of Figure 1). These genes had been implicated in
mouse studies of methotrexate resistance since the mid-1970s
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(Flintoff et al., 1976) and by the early 1980s gene amplification in
experimental animal systems had been described as a mechanism
for resistance to methotrexate (Flintoff et al., 1982). By the mid
1980s, the mechanism had been generalized, at least hypotheti-
cally, to include all classes of anticancer drugs that affected the
DNA of cancer cells. As one of the leaders of the field, the Stanford
biologist Schimke (1984), put it in a review of recent studies: “We
conclude that any number of agents that affect DNA synthesis or
introduce damage into DNA may well facilitate amplification”.
And yet, like the results produced by MDR research, the gene
amplification findings in methotrexate did not translate well into
the clinic. Presenting a new human leukemia cell line to the scien-
tific public, White et al. (1989) noted that previous experimental
work on gene amplification had failed to predict clinical findings.
In particular, they noted that: “Although amplification of DHFR
genes in response to methotrexate exposure is well characterized
experimentally, such gene amplification in human tumor tissue is
not often reported in response to therapy and, when detected, is
low in magnitude” (White et al., 1989). As illustrated by a state-
ment in DeVita et al. (2005), according to which “despite many
years of active investigation, the relative contribution of each of
these different mechanisms to the development of cellular resis-
tance to MTX remains unclear,” the situation remained unchanged
well into the new century.
THE END OF THE ROAD AND THE EMERGENCE OF A NEW
REGIME
The absence of clinical correlations for the numerous experimen-
tal animal systems and in vitro human systems was a common
problem that plagued the study of resistance. As the chapter
on mechanisms of anti-neoplastic drug resistance in the fourth
edition of DeVita et al.’s widely regarded Cancer: Principles and
Practice of Oncology concluded: “Most of the mechanisms of drug
resistance described have been determined in cell culture and ani-
mal models. . . . No comprehensive evaluation of mechanisms of
resistance has been undertaken in human disease” (Morrow and
Cowan, 1993). The following edition (Beck and Dalton, 1997) had
little more to offer in terms of clinical findings but noted, how-
ever, that the mismatch between patients and animals in terms of
thresholds of resistance made “a strong case” for “developing sen-
sitive assays for markers of drug resistance and functional assays
for the same to develop a ‘resistance profile’ of the individual
patient’s tumor.” While clearly not a harbinger of personalized
medicine, the proposal seemed to signal that traditional resistance
studies had entered a cul de sac. Indeed, rather than rearranging
the modalities of the traditional drug classes, the authors alluded
to what would soon become known as targeted therapy, refer-
ring to the “developing knowledge of interactions of drug ‘target’
proteins” as a potent source of “radical change over the next few
years” (Beck and Dalton, 1997). The fifth edition of the equally
highly regarded Holland-Frei Cancer Medicine (2000) concluded
along similar lines: despite clinical efforts to overcome resistance
such as the “rational choice of conventional agents,” the future of
resistance research lay in new agents (Morrow and Cowan, 2000).
And, indeed, Figure 2 displays a number of clusters that concern
the new, targeted agents such as imatinib (followed by dasatinib,
nilotinib), trastuzumab, and gefinitib. These targeted agents have
been developed and tested in relation to specific kinds of cancer.
On the right side of the map we see a green cluster displaying,
in addition to the landmark paper by Daley et al. (1990) demon-
strating that the expression of the bcr/abl protein could induce
chronic myelogenous leukemia, a number of papers (Druker et al.,
1996, 2001; Kantarjian et al., 2002; O’Brien et al., 2003) concern-
ing one of the first and, so far, most successful targeted therapies,
imatinib, deployed against chronic myelogenous leukemia and,
later, gastrointestinal stromal tumor (a map, not shown, restricted
to the 2006–2010 period shows a distinct gastrointestinal stro-
mal tumor-imatinib cluster). As those involved in its development
reported in 2002: “Based on the history of cancer therapeutics,
the development of resistance to targeted agents, like imatinib
could be expected. What was unusual, however, was the rapid-
ity with which resistance mechanisms could be unraveled due to
our thorough understanding of the drug action” (Mellinghoff and
Sawyers, 2002). In the decade since those words were written, an
even deeper knowledge of the drug mechanism has uncovered yet
further mechanisms of resistance (Mahon et al., 2000; Gorre et al.,
2001; Hochhaus et al., 2002; Shah et al., 2002; Vaidya et al., 2012)
and drugs to combat that resistance (Shah et al., 2004): the purple
cluster located at the bottom-right of the map denotes research on
resistance to imatinib. The essential development, in this respect, is
that resistance to targeted drugs, rather than an unqualified failure,
is now seen as proof in principle that the drugs do indeed hit the
target. In other words, “resistance conferring mutations can also
be seen as the inevitable consequence of a drug-imposed selec-
tion process, which in fact confirms the validity of the targeted
therapeutic approach” (Daub et al., 2004).
The other paradigmatic example of targeted therapy,
trastuzumab, followed a similar path (Slamon et al., 2001). As
we have shown in another paper (Cointet et al., 2012), breast can-
cer occupies a place of choice in the recent development of cancer
genomics. On the top of the map we see another green cluster
corresponding to work on resistance to trastuzumab. Although
the precise mechanisms of resistance and action remain unknown
14 years after its FDA approval in 1998 (Stern, 2012) and 25 years
after the initial correlation of HER2 amplification with survival
and relapse (Slamon et al., 1987), multiple pathways, includ-
ing a possible common node in the SRC pathway (Zhang et al.,
2011), have been implicated. Indeed, notwithstanding the absence
of a definitive mechanism, the study of the molecular pathways
involved in trastuzumab resistance has led directly to therapeutic
strategies to overcome resistance. This is the case, for example, with
the Bolero series of clinical trials that target the PI3K/mTOR resis-
tance pathway with everolimus (Tang and Finn, 2012). Similarly,
resistance to BRAF inhibition in melanoma has cast light on the
reactivation of the MAPK pathway as a mechanism of therapeutic
failure thus opening the door for the clinical use of both BRAF
inhibitors and complementary inhibitors of the MAPK pathway
(Villanueva et al., 2011).
In the new world of targeted therapy, spectacular instances
of resistance have continued to give rise to significant break-
throughs. For instance, in Figure 2 we see a cluster related to
studies of samples from non-small cell lung cancer patients treated
at the Massachusetts General Hospital with gefitinib. Those studies
showed that although gefitinib produced dramatic improvement
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in only a small number of patients, those who did respond often
had somatic mutations in the exons that encode for the TK domain
of the EGFR (Lynch et al., 2004; Kobayashi et al., 2005). Researchers
at Harvard and Dana Farber had published similar results the same
year (2004) in Science (Paez et al., 2004; Pao et al., 2005). Analogous
stories can be told in relation to the clusters displayed on Figure 3
that portrays the co-citation patterns of publications during the
last 2 years. The trend is thus clear: whereas the pathways of dis-
ease progression and therapeutic resistance have in the past been
considered separate, distinct processes, they are now treated as
common biopathological pathways (Alexander and Friedl, 2012).
CONCLUSION
As argued by Jones et al. (2011), new scientometric and text analy-
sis techniques as applied to large datasets of publications provide
an innovative way of mapping the structure of a scientific field
and its development (Boyack et al., 2005; Börner, 2010). The maps
we discussed in this paper document a transition from generic
mechanisms of resistance to chemotherapy to a focus on resistance
to targeted therapies and molecular mechanisms of ontogenesis,
a finding that might resonate with many practitioners’ experi-
ences of the field. Our demonstration, however, is based on the
analysis of a comprehensive dataset of publications, the system-
atic resort to quantitative indicators derived from this dataset in
combination with network analysis and NLP algorithms, and data
visualization techniques. As such, it shows that such a transition is
not just a subjective interpretation of the current state of clinical
research in oncology, but can be tracked through the analysis of
changing citation patterns in the literature. Moreover, our analysis
includes a detailed description of connections and structural rela-
tionships between subdomains, thus providing insights into the
differential topology of clusters of publications at different times:
by comparing, for instance, Figure 1 with Figure 3, one can easily
visualize differences in the degree of integration or fragmentation
of subdomains at these two different periods.
Moreover, some of results we report provide an interesting take
on recent debates within oncology, namely whether histological
classifications of the anatomic origin of tumors are still relevant
to cancer treatment in the post-genomic era, or whether treat-
ments should be based solely on the molecular profile of the tumor
without considering histology. Our analysis shows that while mol-
ecular biomarkers and the study of pathways do indeed make-up
a large part of the recent literature, these developments take place
within subdomains that are still best characterized by anatomically
defined diseases. With these new lines of research into the mole-
cular mechanisms of resistance and their relationship to targeted
drugs, the contemporary study of drug resistance in oncology has
succeeded in establishing a greater degree of clinical relevance than
early selection models of resistance. Our analysis also demon-
strates a concomitant shift in the methods used to study resistance,
from an almost exclusive reliance on animal models to a focus on
using human tissue samples and clinical trials as a site of generat-
ing new information about resistance. These findings point to the
growing importance of clinical trials as a site for generating knowl-
edge about basic biological questions such as the mechanisms of
resistance, rather than merely as a site for testing the safety and
efficacy of new drugs.
This historical shift has also effected organizational changes in
the structure of the research field with potential implications for
the future study of resistance. While contemporary trends show
a merging of resistance research with clinical research and even
treatment, they also show, as just noted, the increasing fragmen-
tation of a domain that was once defined by a common interest in
MDR. The trend toward the separation of resistance research activ-
ities into loosely connected disease and treatment-based clusters
suggests an ongoing need for increased communication and col-
laboration between researchers working on the molecular mecha-
nisms of drug resistance. In particular, it raises the thorny issue
of the relation between the traditional division of the oncol-
ogy domain into separate specialties defined by tissue of origin,
and transversal research activities based on common molecular
mechanisms in different kinds of cancer.
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